TMEM2 induces epithelial-mesenchymal transition and promotes resistance to temozolomide in GBM cells

Gao, Lun; Tong, Shiao; Liu, Junhui; Cai, Jiayang; Ye, Zhang; Zhou, Long; Song, Peng; Li, Zhiyang; Ling, Pan; Wei, Hangyu; Hua, Qiuwei; Tian, Daofeng; Cai, Qiang

doi:10.1016/j.heliyon.2023.e16559

Cited by 2 publications

(1 citation statement)

References 23 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, proneural and mesenchymal tumor subtypes reflect two possible states of CSCs, namely proliferation and survival. The transition to the survival state occurs under the influence of hypoxia ( 68 ), cytostatics ( 69 ), irradiation ( 70 , 71 ) and anti-angiogenic therapy ( 72 ). It can be assumed that the reverse transition, triggering tumor relapse, is also precipitated by the influence of the local microenvironment, which activates numerous molecular mechanisms in CSCs ( 73 ), with the canonical Wnt signaling pathway playing a particular role among those mechanisms.…”

Section: CC Plasticity and Resistance To Treatmentmentioning

confidence: 99%

Regulation of cancer stem cells and immunotherapy of glioblastoma (Review)

Kosianova,

Pak,

Bryukhovetskiy

2023

Biomed Rep

View full text Add to dashboard Cite

Glioblastoma (GB) is one of the most adverse diagnoses in oncology. Complex current treatment results in a median survival of 15 months. Resistance to treatment is associated with the presence of cancer stem cells (CSCs). The present review aimed to analyze the mechanisms of CSC plasticity, showing the particular role of β-catenin in regulating vital functions of CSCs, and to describe the molecular mechanisms of Wnt-independent increase of β-catenin levels, which is influenced by the local microenvironment of CSCs. The present review also analyzed the reasons for the low effectiveness of using medication in the regulation of CSCs, and proposed the development of immunotherapy scenarios with tumor cell vaccines, containing heterogenous cancer cells able of producing a multidirectional antineoplastic immune response. Additionally, the possibility of managing lymphopenia by transplanting hematopoietic stem cells from a healthy sibling and using clofazimine or other repurposed drugs that reduce β-catenin concentration in CSCs was discussed in the present study. Contents 1. Introduction 2. Principles of GB treatment 3. CC plasticity and resistance to treatment 4. Wnt signaling pathway and the microenvironment of CSCs 5. Targeted therapy and CSC plasticity 6. β-catenin inhibitors and CT 7. CSC microenvironment, immunotherapy and immunodeficiency 8. HSCs and immunotherapy 9. Conclusion

show abstract

Section: CC Plasticity and Resistance To Treatmentmentioning

confidence: 99%

Regulation of cancer stem cells and immunotherapy of glioblastoma (Review)

Kosianova,

Pak,

Bryukhovetskiy

2023

Biomed Rep

View full text Add to dashboard Cite

show abstract

mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses

Azimi,

Yazdanian,

Ahmadiani

2024

BMC Cancer

View full text Add to dashboard Cite

Background Glioblastoma multiforme (GBM) is a type of fast-growing brain glioma associated with a very poor prognosis. This study aims to identify key genes whose expression is associated with the overall survival (OS) in patients with GBM. Methods A systematic review was performed using PubMed, Scopus, Cochrane, and Web of Science up to Journey 2024. Two researchers independently extracted the data and assessed the study quality according to the New Castle Ottawa scale (NOS). The genes whose expression was found to be associated with survival were identified and considered in a subsequent bioinformatic study. The products of these genes were also analyzed considering protein-protein interaction (PPI) relationship analysis using STRING. Additionally, the most important genes associated with GBM patients’ survival were also identified using the Cytoscape 3.9.0 software. For final validation, GEPIA and CGGA (mRNAseq_325 and mRNAseq_693) databases were used to conduct OS analyses. Gene set enrichment analysis was performed with GO Biological Process 2023. Results From an initial search of 4104 articles, 255 studies were included from 24 countries. Studies described 613 unique genes whose mRNAs were significantly associated with OS in GBM patients, of which 107 were described in 2 or more studies. Based on the NOS, 131 studies were of high quality, while 124 were considered as low-quality studies. According to the PPI network, 31 key target genes were identified. Pathway analysis revealed five hub genes (IL6, NOTCH1, TGFB1, EGFR, and KDR). However, in the validation study, only, the FN1 gene was significant in three cohorts. Conclusion We successfully identified the most important 31 genes whose products may be considered as potential prognosis biomarkers as well as candidate target genes for innovative therapy of GBM tumors.

show abstract

TMEM2 induces epithelial-mesenchymal transition and promotes resistance to temozolomide in GBM cells

Cited by 2 publications

References 23 publications

Regulation of cancer stem cells and immunotherapy of glioblastoma (Review)

Regulation of cancer stem cells and immunotherapy of glioblastoma (Review)

mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses

Contact Info

Product

Resources

About